Targeted therapeutics
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
1. A method for treating a subject having a disease or disorder comprising administering a therapeutically effective amount of at least one binding moiety-drug conjugate (SDC-TRAP) to the subject, thereby treating the disease or disorder, wherein the SDC-TRAP comprises a binding moiety and an effector moiety, wherein the binding moiety binds to Hsp90 and wherein the effector moiety is a cytotoxic agent selected from the group consisting of flavopiridol, lapatinib, axitinib, vemurafenib, imatinib, staurosporine, panobinostat, carfilzomib, INCB024360 and methyl tryptophan or (a) fragment(s) thereof, and wherein the binding moiety and the effector moiety are covalently attached, wherein the disease or disorder is cancer, wherein the cancer is selected from the group consisting of lung cancer, colon cancer, breast cancer, skin cancer, and bladder cancer.